Y-Biologics, Inc. (KOSDAQ:338840)

Y-Biologics Statistics

Total Valuation

Y-Biologics has a market cap or net worth of KRW 377.93 billion. The enterprise value is 348.42 billion.

Market Cap	377.93B
Enterprise Value	348.42B

Important Dates

Earnings Date	n/a
Ex-Dividend Date	n/a

Share Statistics

Y-Biologics has 15.18 million shares outstanding. The number of shares has increased by 0.79% in one year.

Current Share Class	15.18M
Shares Outstanding	15.18M
Shares Change (YoY)	+0.79%
Shares Change (QoQ)	+0.11%
Owned by Insiders (%)	29.08%
Owned by Institutions (%)	3.32%
Float	10.69M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	129.74
PB Ratio	14.21
P/TBV Ratio	14.50
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-8.29
EV / Sales	119.61
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-50.75

Financial Position

The company has a current ratio of 36.16, with a Debt / Equity ratio of 0.55.

Current Ratio	36.16
Quick Ratio	35.93
Debt / Equity	0.55
Debt / EBITDA	n/a
Debt / FCF	-2.15
Interest Coverage	-7.36

Financial Efficiency

Return on equity (ROE) is -181.79% and return on invested capital (ROIC) is -18.76%.

Return on Equity (ROE)	-181.79%
Return on Assets (ROA)	-14.95%
Return on Invested Capital (ROIC)	-18.76%
Return on Capital Employed (ROCE)	-16.99%
Weighted Average Cost of Capital (WACC)	9.59%
Revenue Per Employee	n/a
Profits Per Employee	n/a
Employee Count	n/a
Asset Turnover	0.08
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +305.54% in the last 52 weeks. The beta is 0.99, so Y-Biologics's price volatility has been similar to the market average.

Beta (5Y)	0.99
52-Week Price Change	+305.54%
50-Day Moving Average	27,096.00
200-Day Moving Average	19,738.50
Relative Strength Index (RSI)	42.30
Average Volume (20 Days)	339,319

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Y-Biologics had revenue of KRW 2.91 billion and -42.02 billion in losses. Loss per share was -2,822.00.

Revenue	2.91B
Gross Profit	2.29B
Operating Income	-9.27B
Pretax Income	-42.02B
Net Income	-42.02B
EBITDA	-7.34B
EBIT	-9.27B
Loss Per Share	-2,822.00

Balance Sheet

The company has 44.27 billion in cash and 14.75 billion in debt, with a net cash position of 29.52 billion or 1,944.63 per share.

Cash & Cash Equivalents	44.27B
Total Debt	14.75B
Net Cash	29.52B
Net Cash Per Share	1,944.63
Equity (Book Value)	26.60B
Book Value Per Share	1,775.21
Working Capital	43.58B

Cash Flow

In the last 12 months, operating cash flow was -5.84 billion and capital expenditures -1.02 billion, giving a free cash flow of -6.86 billion.

Operating Cash Flow	-5.84B
Capital Expenditures	-1.02B
Depreciation & Amortization	1.93B
Net Borrowing	34.33B
Free Cash Flow	-6.86B
FCF Per Share	-452.28

Margins

Gross Margin	78.75%
Operating Margin	-318.20%
Pretax Margin	-1,442.67%
Profit Margin	n/a
EBITDA Margin	-251.87%
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Y-Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.79%
Shareholder Yield	-0.79%
Earnings Yield	-11.12%
FCF Yield	-1.82%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Y-Biologics has an Altman Z-Score of 0.2 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	0.2
Piotroski F-Score	3